News

August 10, 2017August 10, 2017

Verona Pharma Updates Clinical Development of COPD Therapy RPL554

News

Verona Pharma recently announced clinical development updates and interim results for the first half of 2017 for RPL554 as a treatment for chronic obstructive pulmonary disease (COPD) with the ... Read more

August 8, 2017August 8, 2017

European Union Approves Chiesi’s COPD Maintenance Therapy Trimbow

News

The European Union has approved Trimbow as a maintenance treatment for adults with moderate to severe chronic obstructive pulmonary disease. Trimbow, developed by Italy’s Chiesi Group, is the first triple-combination ... Read more

July 28, 2017July 28, 2017

RPL554 Administered to First Patients in Phase 2b Clinical Study for COPD Treatment

News

Verona Pharma recently dosed the first patients in its Phase 2b clinical trial evaluating RPL554 as a maintenance treatment for chronic obstructive pulmonary disease (COPD). RPL554 is a first-in-class dual ... Read more

July 27, 2017July 27, 2017

Novavax’s Lung Virus Vaccine Provokes Immune Response, Reduces COPD Hospitalizations, Trials Show

News

A vaccine that Novavax developed to deter the virus that causes most lung infections generated the desired immune response in children, and was safe, according to clinical trials. The trials dealt ... Read more

July 25, 2017July 25, 2017

Phase 3 Trial Demonstrates Improved Safety Profile of Revefenacin for Moderate to Very Severe COPD

News

Results of a Phase 3 trial of the investigational drug revefenacin (TD-4208) for the treatment of moderate to very severe chronic obstructive pulmonary disease (COPD) demonstrated the therapy is well ... Read more

July 20, 2017July 20, 2017

Pulmonary Structural Changes Regulate Lung Bacteria in COPD Patients, Study Finds

News

Severe cases of chronic obstructive pulmonary disease (COPD) can lead to structural changes in the lungs. These changes not only aggravate lung function, they can also alter the bacterial ... Read more

July 18, 2017July 18, 2017

Sunovion Divesting U.S. Market Rights to Asthma and Allergic Rhinitis Therapies to Covis Pharma

News

Sunovion Pharmaceuticals will divest its U.S. market rights for ciclesonide products for the treatment of asthma and allergic rhinitis to Covis Pharma. With this agreement, Sunovion confirms its focus on ... Read more

July 14, 2017July 14, 2017

Cytokinetics Launches Phase 1b Trial for COPD Therapy Candidate CK-2127107

News

Cytokinetics recently launched a Phase 1b clinical trial designed to evaluate the effect of CK-2127107 on physical function in older adults with limited mobility due to diseases associated with muscular weakness ... Read more

July 11, 2017July 11, 2017

Positive Airway Pressure Therapy Might Reduce COPD Hospitalizations, But Few Patients Receive It

News

Although studies show that continuous positive airway pressure (PAP) therapy can reduce hospitalizations among patients with chronic obstructive pulmonary disease (COPD), less than 8 percent of patients receive this ... Read more

July 6, 2017July 6, 2017

FDA Agrees to New Review of the SUN-101/e-Flow COPD Treatment System

News

U.S. regulators have agreed to Sunovion Pharmaceuticals’ request for another review of its SUN-101/e-Flow system for treating chronic obstructive pulmonary disease. The review will cover a New Drug Application that Sunovion resubmitted after the Federal ... Read more